Published: 2018-11-26

Role of pre-treatment neutrophil to lymphocyte ratio as a diagnostic marker of malignancy in breast carcinoma patients: a study in a tertiary care centre

Shruti Srivastava, Chandrashekhar Indoria


Background: Inflammation is closely associated with cancer. Inflammation maintains and promotes cancer growth by causing tumor tissue remodelling and angiogenesis. It also helps in metastasis and helps tumor cells to survive by suppressing anti-cancer innate immune response. Recent studies have suggested use of Neutrophil lymphocyte ratio (NLR) for evaluation of systemic inflammation. Present study was undertaken with an aim to compare NLR among patients with malignant breast neoplasm with and without metastasis.

Methods: This was a cross sectional observational study comprising of 179 women with breast neoplasm. Patients were categorized into two subgroups of benign proliferative breast mass and malignant breast mass (with or without metastasis). Data was collected from pre intervention complete blood count reports of all patients. To obtain NLR values neutrophil count were divided by lymphocyte counts. A comparison of NLR values in different subgroups of the patients was performed.

Results: Mean neutrophil values in benign and malignant subgroups were 64.02±7.9 and 70.75±9.2 respectively. Mean lymphocyte count in benign and malignant subgroups was 27.527±7.565 and 20.220±7.354 respectively. Difference in mean values for neutrophils and lymphocytes was not significant in benign and malignant subgroups. Significant difference was present in values of NLR among benign and malignant subgroups, but within malignant subgroup no significant difference was present among patients with or without metastasis.

Conclusions: Present study findings supported that pre-intervention Neutrophil Lymphocyte ratio is a promising biomarker of malignancy.


Breast carcinoma, Benign, Neutrophil, Lymphocyte, Ratio

Full Text:



Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86.

Gupta S. Breast cancer. Indian experience, data, and evidence. South Asian J Cancer. 2016;5(3):85-6.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.

McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treatment Reviews. 2013 Aug 1;39(5):534-40.

Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer. Critical Reviews Oncol Hematol. 2013 Oct 1;88(1):218-30.

Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004 Nov 1;9(6):606-16.

Ozyalvacli G, Yesil C, Kargi E, Kizildag B, Kilitci A, Yilmaz F. Diagnostic and prognostic importance of the neutrophil lymphocyte ratio in breast cancer. Asian Pac J Cancer Prev. 2014 Jan 1;15(23):10363-6.

Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G. Roles of neutrophils in cancer growth and progression. J Leukocyte Biol. 2018 Mar;103(3):457-64.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004 Aug 1;21(2):137-48.

Lin CF, Lin CM, Lee KY, Wu SY, Feng PH, Chen KY, et al. Escape from IFN-γ-dependent immunosurveillance in tumorigenesis. J Biomed Sci. 2017 Dec;24(1):10.

Hadrup S, Donia M, thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenvironment. 2013 Aug 1;6(2):123-33.

El-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987 Oct 1;139(7):2406-13.

Shau HY, Kim A. Suppression of lymphokine-activated killer induction by neutrophils. J Immunol. 1988 Dec 15;141(12):4395-402.

Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy. 2003;83:182-203.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009 Jul 1;30(7):1073-81.

Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, Quigley JP. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia. 2014 Oct 1;16(10):771-88.

Malorni L, Shetty PB, Dc Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, et al Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow‑up Breast Cancer Res Treatment. 2012;136(3):795-804.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surgical Oncol. 2016 Apr 1;23(4):1104-10.

Faria SS, Fernandes Jr PC, Silva MJ, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancer Med Sci. 2016;10.

Yersal Ö, Çetinkünar S, Aktimur R, Aziret M, Özdaş S, Erdem H, et al. Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes. Asian Pacific J Cancer Prevention. 2017;18(8):2227.

Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?. Lung Cancer. 2015;18:20.

Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH, et al. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Current Oncology. 2018;25(2):e113-9.

Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil‐to‐lymphocyte ratio in breast cancer. FEBS Open Bio. 2015 Jan 1;5(1):502-7.

Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Therapy. 2016;9:5567.

Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017 Dec;19(1):2.